Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease

Series A-2 led by Hatteras Venture Partners and Biohaven

Donnie McGrath, M.D., and Seth Rudnick, M.D., join Artizan’s board of directors

NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) — Artizan Biosciences, Inc. (“Artizan”), a biotechnology company focused on addressing inflammatory diseases involving the human intestinal microbiota, today announced the company has raised $11 million in a Series A-2 financing led by existing investor Hatteras Venture Partners and new investor Biohaven Therapeutics Ltd. (“Biohaven”). Additional new investor CT Innovations and existing investors Elm Street Ventures and Osage University Partners also participated in the round. Artizan will use the proceeds to continue advancing the preclinical research and development of its lead program for inflammatory bowel disease (“IBD”), which is anticipated to enter the clinic in 2022, as well as to explore additional disease targets.